InVEST: Tiered Off-Target Screening For Every Development Stage
InVEST (In Vitro Evaluation of Safety and Toxicity) safety panels deliver comprehensive off-target screening across GPCRs, ion channels, transporters, kinases, nuclear receptors, and other enzymatic targets.
Reaction Biology's safety platform covers the industry standard set of targets for detecting potential adverse effects early in the drug development process, ensuring a safer, more efficient path from discovery to clinical trials
Six panels, with 18, 44, 59, or 77 target options, includefunctional assays (patch clamp, FLIPR, reporter gene) for agonist/antagonist differentiation, plus binding assays for efficient coverage across remaining targets.
InVEST18— Core Liability Screen
InVEST44 — Hit-to-Lead Essentials
InVEST59— Extended Selectivity
InVEST77 — Comprehensive Profiling
InVEST CYP — Metabolic Safety Panel
InVEST PDE — Phosphodiesterase Panel
Kinases profiled at physiological 1mM ATP. All panels return data in 10 business days from our Malvern, PA facility.
10 business day turnaround for all panel sizes (18–77 targets)
Tiered panels aligned to development stage: hit confirmation → lead optimization → candidate selection
Functional assays (patch clamp, FLIPR, reporter gene) plus binding assays
All kinases at 1mM ATP for translationally relevant IC50 values
Single-concentration or full dose-response IC50/EC50 for any target
US-based single-site execution with monthly screening runs
Related resources
In Vitro Safety Pharmacology Profiling
Screen your compounds against a broad range of targets that may cause adverse drug reactions in humans including receptors, transporters, enzymes, and ion channels.
Determining a dosing schedule and route of administration for in vivo efficacy testing. Gain insights into whether your drug act on its target in vivo.
